📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Sumitomo Chemical Q3 Revenue Dips 12% to ₹568 Cr; Margins Expand to 47.4%
Sumitomo Chemical India reported a 12% YoY decline in Q3FY26 revenue to ₹568 crore, largely due to the strategic discontinuation of the low-margin Animal Nutrition distribution business and soft domestic demand. Despite the revenue dip, gross margins expanded significantly by 522 bps to 47.4% through a superior product mix and disciplined pricing. Net profit fell 13% YoY to ₹75.8 crore, weighed down by a one-time exceptional charge of ₹16.1 crore related to newly notified Labour Codes. The company provided clarity on its ₹160 crore capex projects, with commercialization expected between Q4 FY28 and Q2 FY29.
Key Highlights
Q3FY26 revenue fell 12% YoY to ₹568 crore, while 9MFY26 revenue grew 3% to ₹2,555 crore.
Gross margins improved to 47.4% in Q3 from 42.1% YoY, supported by the exit from the low-margin AND business (₹72 crore impact).
Net Profit for Q3 stood at ₹75.8 crore, impacted by a ₹16.1 crore one-time exceptional charge for Labour Code compliance.
Announced commercialization timelines for ₹150 crore Dahej project (Q2 FY29) and ₹10 crore Tarapur project (Q4 FY28).
Maintains a strong balance sheet with cash and cash equivalents of approximately ₹2,163 crore as of December 31, 2025.
💼 Action for Investors
Investors should focus on the significant margin expansion and the company's transition toward high-margin patented molecules from its parent company. While short-term domestic demand remains soft, the strong cash position and upcoming capex provide a solid long-term growth outlook.
Sumitomo Chemical Q3 PAT Falls 13% to ₹76 Cr on One-time Charge; Margins Expand 522 bps
Sumitomo Chemical India reported a 12% YoY decline in Q3FY26 revenue to ₹568 crore, largely due to the strategic discontinuation of the low-margin Animal Nutrition distribution business. Despite the revenue dip, gross margins expanded significantly by 522 bps to 47.4% due to a favorable product mix and disciplined pricing. Net profit fell 13% to ₹75.8 crore, primarily impacted by a one-time exceptional charge of ₹16.1 crore related to new Labour Code provisions. The company also announced a strategic ₹150 crore capex for its Dahej site to manufacture patented molecules for its Japanese parent company.
Key Highlights
Q3 Revenue declined 12% YoY to ₹568 crore, impacted by a ₹72 crore revenue loss from discontinued low-margin business.
Gross Profit Margin improved to 47.4% from 42.1% YoY, while EBITDA margin rose to 17.5%.
Board approved ₹150 crore capex for a herbicide intermediate plant at Dahej for global supply to the parent company.
Net Profit of ₹75.8 crore was affected by a ₹16.1 crore one-time exceptional charge; excluding this, PBT remained stable.
Cash and cash equivalents stood at a robust ₹2,163 crore as of December 31, 2025.
💼 Action for Investors
Investors should look past the headline PAT decline as it was driven by a one-time charge and the exit from low-margin segments. The significant margin expansion and the new capex for the parent company's patented molecules signal a positive long-term shift toward higher-value manufacturing.
Sumitomo Chemical India Files Q3 FY26 Results; Reports Zero Loan Defaults
Sumitomo Chemical India Limited has submitted its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting concluded on January 27, 2026, confirming the approval of these results without any audit qualifications. The company reported zero deviations in the use of proceeds from public or preferential issues. Additionally, no defaults on loans or debt securities were reported for the period.
Key Highlights
Board approved unaudited standalone and consolidated financial results for Q3 and 9M ended Dec 31, 2025
Company confirmed zero outstanding defaults on loans and debt securities as of the reporting date
Reported zero deviations or variations in the utilization of proceeds from public or rights issues
The financial results were submitted with an unqualified audit opinion for the period ending December 2025
Board meeting for result approval was conducted between 12:12 P.M. and 01:51 P.M. on January 27, 2026
💼 Action for Investors
Investors should examine the detailed Annexure I for specific revenue and margin trends to assess operational performance. The lack of audit qualifications and debt defaults indicates a stable regulatory and credit profile.